ResoTher Pharma A/S: Financial statements 2023
CVR: 37852406
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
ResoTher Pharma A/S (CVR 37852406) has filed annual accounts for 2023. Equity in the 2023 report amounted to DKK 20,760,000. The solvency ratio was 95.4%. The company had 2 employees in the financial year.
- Equity
- DKK 20,760,000
- Total Assets
- DKK 21,761,000
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | - | - | 20.8M | 2 |
| 2022 | - | - | -27.2M | 12.2M | 3 |
| 2021 | - | - | -11.7M | 38.6M | 3 |
| 2020 | - | - | -5.2M | -560K | 2 |
| 2019 | - | - | -3.9M | 1.7M | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
ResoTher Pharma A/S has published its annual report for 2022. The net result was DKK -27,218,000.
As of June 28, 2023, Roderick John Flower has joined the board of directors of ResoTher Pharma A/S.
As of February 1, 2023, Anders Kronborg is registered as adm. dir. of ResoTher Pharma A/S.
As of January 31, 2023, Lone Merete Veng has stepped down as adm. dir. of ResoTher Pharma A/S.
About ResoTher Pharma A/S
ResoTher Pharma A/S is a Danish company of the type Aktieselskab based in Holte, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ResoTher Pharma ApS. The management consists of Anders Kronborg. The board consists of Rebecca Anne Morison (chair), Henrik Stage, Jeppe Øvli Øvlesen and Michael Østerlund Madsen. The company is owned by Quantass ApS and TJ Biotech Holding ApS. The company has 4 employees (2026). Equity in the 2025 report amounted to DKK 12,132,000.